RIBOMIC Announces Interim Report on the Phase 2 Long-Term Clinical Trial of Umedaptanib Pegol in the Treatment of Achondroplasia
Filed with TSE · · 3 pages · English
Earlier from Ribomic
- [Delayed]RIBOMIC Announces No Safety Concerns After Three Months of 1mg/kg Weekly Treatment with Umedaptanib Pegol in Achondroplasia Phase2 Study
- RIBOMIC Announces Completion of Clinical Trial Site Establishment for the Phase 3 Clinical Trial of Umedaptanib Pegol in Achondroplasia
- Summary of Non-Consolidated Financial Results for the Three Months Ended June 30 2026(Based on Japanese GAAP)
- RIBOMIC Announces First Patient In (FPI) in the Phase 3 Clinical Trial of Umedaptanib Pegol in the Treatment of Achondroplasia